Neuronetics announces participation at CTMSS Meeting, presenting TMS research data and showcasing NeuroStar therapy innovations.
Quiver AI Summary
Neuronetics, Inc., a medical technology company focused on mental health, has announced key updates regarding its NeuroStar therapy. The company will be a Silver Sponsor at the 13th Annual Clinical TMS Society Meeting in San Diego, where it will present findings from its extensive TrakStar data set, highlighting a comparative analysis of TMS treatment outcomes using its proprietary device versus a competitor's. Notably, NeuroStar will showcase research on the effectiveness of TMS in treating late-life depression and the clinical outcomes of patients using NeuroStar and Brainsway devices. Additionally, Neuronetics is exploring the use of personalized qEEG-informed protocols for TMS therapy through its Greenbrook subsidiary. With over 7.4 million NeuroStar treatments delivered, the company emphasizes its commitment to advancing mental health care through research and innovation.
Potential Positives
- Neuronetics is participating as a Silver Sponsor at the prestigious 13th Annual Clinical TMS Society Meeting, highlighting its commitment to mental health innovation.
- The presentation of real-world data comparing NeuroStar's device efficacy to competitors provides valuable insights and reinforces its position as a leader in TMS therapy.
- Greenbrook Mental Wellness Centers, as a subsidiary of Neuronetics, has initiated a promising program to explore personalized TMS protocols, showcasing ongoing research and development in treatment methodologies.
- Neuronetics' NeuroStar Advanced Therapy remains the leading TMS treatment for major depressive disorder, with over 7.4 million treatments delivered, backed by the world’s largest depression outcomes registry.
Potential Negatives
- Press release does not address potential competitive challenges or market saturation in the TMS therapy sector, which could impact future growth.
- It highlights that data from their own device (NeuroStar) will be compared against a competitor (Brainsway), raising questions about competitive efficacy.
- The statement regarding the program to evaluate personalized protocols may suggest a reliance on new methods to improve outcomes, which could imply existing methods are less effective.
FAQ
What is NeuroStar's role at the CTMSS Meeting?
NeuroStar is a Silver Sponsor and will present two poster presentations related to their TMS therapy data.
What are the main findings being presented by NeuroStar?
NeuroStar will present effective TMS treatment outcomes for elderly adults and compare the performance of NeuroStar and Brainsway devices.
When will NeuroStar's presentations take place?
The presentations are scheduled for June 13th at 4:00 PM PDT during the CTMSS Meeting.
How does NeuroStar improve mental health treatments?
Neuronetics develops non-drug, noninvasive TMS therapies to enhance treatment outcomes for patients with mental health disorders.
What additional treatments does Greenbrook offer?
Greenbrook also provides SPRAVATO® nasal spray for treatment-resistant depression alongside NeuroStar TMS therapy.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$STIM Insider Trading Activity
$STIM insiders have traded $STIM stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $STIM stock by insiders over the last 6 months:
- STEPHEN FURLONG (EVP, CFO and Treasurer) has made 0 purchases and 6 sales selling 244,855 shares for an estimated $1,022,974.
- KEITH J SULLIVAN (President and CEO) has made 0 purchases and 3 sales selling 91,366 shares for an estimated $363,690.
- WILLIAM ANDREW MACAN (EVP, GC, CCO and CS) has made 0 purchases and 4 sales selling 33,487 shares for an estimated $132,726.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$STIM Hedge Fund Activity
We have seen 71 institutional investors add shares of $STIM stock to their portfolio, and 28 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KENT LAKE PR LLC removed 2,077,848 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $3,345,335
- CANNELL CAPITAL LLC removed 1,314,266 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $2,115,968
- IKARIAN CAPITAL, LLC added 1,100,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $4,048,000
- VANGUARD GROUP INC added 1,024,680 shares (+80.0%) to their portfolio in Q1 2025, for an estimated $3,770,822
- MANATUCK HILL PARTNERS, LLC added 920,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $3,385,600
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 761,911 shares (+inf%) to their portfolio in Q1 2025, for an estimated $2,803,832
- MILLENNIUM MANAGEMENT LLC added 657,725 shares (+inf%) to their portfolio in Q1 2025, for an estimated $2,420,428
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$STIM Analyst Ratings
Wall Street analysts have issued reports on $STIM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Outperform" rating on 03/05/2025
To track analyst ratings and price targets for $STIM, check out Quiver Quantitative's $STIM forecast page.
Full Release
MALVERN. Pa., June 10, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, is proud to share two significant updates underscoring its ongoing commitment to clinical excellence and innovation in mental health care.
This week, NeuroStar will attend the 13th Annual Clinical TMS Society (CTMSS) Meeting, taking place June 11–14 in San Diego, CA as a Silver Sponsor. NeuroStar will present two poster presentations derived from the TrakStar ® data set, the largest real-world outcomes database in TMS. Data highlights include a retrospective analysis of Greenbrook’s multi-site study, providing a direct comparison of clinical outcomes between NeuroStar’s proprietary Figure-8 coil and Brainsway’s H-coil in the treatment of depression, offering new insight into device-specific performance. As part of the meeting, the Company will participate in the PULSES Course , a foundational training session for new and experienced TMS providers. Additionally, NeuroStar will exhibit at booth #303.
“The data and research initiatives reflect the scientific excellence NeuroStar is known for and are a continuation of our reputation as the leader in contributing to the scientific literature in the psychiatric community,” said Cory Anderson, Chief Technology Officer of Neuronetics. “We will continue to lead the field and put patient outcomes first by investing in valuable research to optimize TMS efficacy and expand its use into new populations and protocols.”
The following data will be presented at the CTMSS Meeting:
Age is Just a Number: Real-world effectiveness of TMS in late-life depression
- Presenter: Dr. Eleanor Cole, Senior Director of Clinical Innovation, Neuronetics Inc.
- Overview: Dr. Cole will present the largest-to-date analysis of elderly adults (age 70 and older) with Major Depressive Disorder (MDD) treated with TMS.
-
Presentation Date: June 13
th
at 4:00 PM PDT
Clinical Outcomes in Patients Treated with NeuroStar and Brainsway TMS Therapy Devices
- Presenter: Cory Anderson, Chief Technology Officer, Neuronetics Inc.
- Overview: Mr. Anderson will present data from a retrospective analysis of data from 200 Greenbrook centers evaluating the real-world efficacy of TMS therapy delivered using NeuroStar or Brainsway devices.
-
Presentation Date: June 13
th
at 4:00 PM PDT
Greenbrook Mental Wellness Centers, a wholly owned subsidiary of Neuronetics, has initiated a program to evaluate the feasibility of using personalized qEEG-informed protocols to deliver TMS therapy using the NeuroStar TMS System. To date, the program has demonstrated operational feasibility and the ability to successfully deliver the protocols using a commercially available NeuroStar TMS System. The Company looks forward to sharing their findings in the near future.
For more information about NeuroStar TMS Therapy, please visit www.neurostar.com .
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.4 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO
®
(esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.
1
Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression.
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com .
Neuronetics Contact:
Investors:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
[email protected]
Media:
EvolveMKD
646.517.4220
[email protected]
1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO ® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO ® . For more important safety information about SPRAVATO®, please visit spravatohcp.com.
